Our single-institutional experience over 25 years demonstrates that local treatment with surgery or SBRT for clinical stage I SCLC is safe and effective, with survivals lower than similar stage non-small-cell carcinoma patients. However, our results compare favorably with prior small-cell surgical series and far better than reported results of chemoradiotherapy for similar stage patients, thereby validating current recommendations for employing surgery or SBRT for stage I SCLC.
Keyphrases
- end stage renal disease
- minimally invasive
- radiation therapy
- coronary artery bypass
- ejection fraction
- newly diagnosed
- chronic kidney disease
- single cell
- peritoneal dialysis
- squamous cell carcinoma
- cell therapy
- locally advanced
- early stage
- stem cells
- rectal cancer
- surgical site infection
- mesenchymal stem cells
- clinical practice
- radiation induced
- patient reported
- replacement therapy